SAMAD SAM 4

What Happened Samad Sam, Executive Vice President & Chief Financial Officer of Quest Diagnostics (DGX), was granted 108 restricted share units on April 20, 2026. The filing reports an acquisition value of $194.70 per share, totaling approximately $21,027. This transaction is an award/grant (not an open-market purchase or sale).

Key Details

• Transaction date: April 20, 2026; reported price: $194.70; total value: ~$21,027.
• Filing date: April 24, 2026 (Form 4 covering the April 20 transaction); filing appears timely.
• Shares owned after the transaction: Not disclosed in the Form 4.
• Footnotes: F1 indicates these are restricted share units (RSUs). F2 describes shares acquired via a dividend reinvestment plan that the filer elected to report early on this Form 4 (normally eligible for deferred reporting on Form 5).
• Transaction type code: A (award/grant).

Context RSU grants are a common form of executive compensation and typically vest over time; they are not the same as an immediate market purchase and do not by themselves indicate the insider is buying or selling for investment reasons. This filing is informational and factual—no inference about the CFO’s market view should be drawn from the award alone.